FIG 5.

URMC-099 treatment increases RSV and SeV infection. (A) HeLa cells were infected with the RSV A2 strain (MOI = 0.5) in the presence of various concentrations of URMC-099 for 48 h. Viral protein levels were determined by Western blotting. (B) 293T cells were infected with SeV (MOI = 0.5) in the presence of various concentrations of URMC-099 for 24 h. Viral protein levels were determined by Western blotting. (C and D) An ISRE promoter-driven reporter construct was transfected into SNB-19 cells, in combination with transfection of an RIG-I-N overexpression plasmid (C) or infection with NDV (D), and the cells were then treated with various concentrations of URMC-099 for 24 h. Luciferase activity was determined. The x axis indicates the concentrations of URMC-099 for the drug treatment group. For the non-drug-treatment group, the x axis indicates the corresponding volume of DMSO solvent. (E and F) An experimental design similar to that described in panels C and D was used, except for the substitution of the ISRE reporter with an IFN-β promoter-driven reporter.